Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.19.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 13, 2018
Dec. 10, 2015
Mar. 28, 2019
Feb. 14, 2019
Jul. 28, 2016
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2017
Nov. 20, 2015
Oct. 19, 2015
Lease expiration date           Jun. 30, 2019          
Intangible assets , carrying value             $ 0        
Grant awarded from NIDA           $ 5,674,268          
Grants receivable from NIDA in year one           2,842,430          
Grants receivable from NIDA in year two           2,831,838          
Grants received from NIDA           224,059          
Revenue recognized related to NIDA grant           224,059          
Deffered revenue - grant           66,000        
Operating leases [Member]                      
Lease expiration date       Sep. 30, 2024              
Rent expense escalation, description       The extended lease has escalating payments from $5,522 per month to $6,552 per month              
Extension of lease term, description       The Company extended the term of its lease for an additional 63 months beginning July 1, 2019 (at expiry of the original lease)              
Alpine Creek Capital Partners LLC [Member]                      
Total royalty payable   $ 405,000                  
Deposit amount                   $ 55,000  
Cancellation of secured promissory note                     $ 55,000
Payables to the Company   295,000                  
Payables to Alpine Creek   $ 1,215,000                  
Payable commitment description   In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories                  
Payable per treatment sold   $ 100                  
Profit holding percentage   50.00%                  
Therakine, Ltd. [Member]                      
License cost         $ 2,750,000            
Aggregate purchase price         $ 250,000 $ 250,000   $ 250,000      
Escrow deposit             75,000   $ 75,000    
Impairment loss             $ 250,000        
Therakine, Ltd. [Member] | Maximum [Member]                      
Sales of products         12.00%            
Therakine, Ltd. [Member] | Minimum [Member]                      
Sales of products         5.00%            
Lucido Subscription and Royalty Agreement [Member]                      
Subscription and royalty agreement description     Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”)                
Description for the use of proceeds under agreement     The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development                
Employment Agreements [Member] | Tom Welch [Member]                      
Annual salary $ 150,000                    
Monthly car allowance and reimbursements for health and medical insurance $ 500                    
Stock option period 10 years                    
Stock options to purchase common shares 75,000                    
Exercise price $ 14.00                    
Employment Agreements [Member] | Ms. Lourdes Felix [Member]                      
Annual salary $ 175,000                    
Monthly car allowance and reimbursements for health and medical insurance $ 500                    
Stock option period 10 years                    
Stock options to purchase common shares 75,000                    
Exercise price $ 14.00                    
Employment Agreements [Member] | Brady Granier [Member]                      
Annual salary $ 175,000                    
Monthly car allowance and reimbursements for health and medical insurance $ 500                    
Stock option period 10 years                    
Stock options to purchase common shares 75,000                    
Exercise price $ 14.00